Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Sector Analysis

Pharmaceutical Preparations

Standard Industrial Classification: SIC 2834

Industry Insider Sentiment Analysis

The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.

Filing Date Trade Date Ticker Company Reporting Person Relationship Type Price Qty Total, $ Owned After
2026-03-03 01:05 2026-02-26 EDSA Edesa Biotech, Inc. Nijhawan Pardeep Director, Officer, 10% owner BUY $1.96 50,571 $99,175 371,702
2026-03-03 01:06 2026-02-26 JAZZ Jazz Pharmaceuticals plc Patil Neena M Officer OPT+S $191.56 55,600 $10,650,480 58,818
2026-03-03 00:34 2026-02-26 NUVL Nuvalent, Inc. Noci Darlene Officer OPT+S $103.03 5,500 $566,682 58,117
2026-03-03 00:22 2026-02-26 BCAX Bicara Therapeutics Inc. RA CAPITAL MANAGEMENT, L.P. Director, 10% owner BUY $16.00 300,000 $4,800,000 4,603,418
2026-03-03 00:08 2026-02-27 ALNY Alnylam Pharmaceuticals Inc. Garg Pushkal Officer OPT+S $331.34 4,627 $1,533,100 22,129
2026-03-03 00:10 2026-02-26 VRTX VERTEX PHARMACEUTICALS INC / MA Ambrose Kristen Officer SELL $483.36 357 $172,560 6,624
2026-03-02 22:16 2026-02-27 ABCL AbCellera Biologics Inc. Thermopylae Holdings Ltd. 10% owner BUY $3.44 38,000 $130,720 56,134,097
2026-03-02 17:15 2026-02-27 FBLG FibroBiologics, Inc. GARCIA RUBEN A Officer BUY $0.33 40,000 $13,056 180,000
2026-03-02 16:00 2026-02-27 PVLA PALVELLA THERAPEUTICS, INC. HERON ELAINE J Director BUY $125.00 2,400 $300,000 47,812
2026-03-02 16:00 2026-02-27 PVLA PALVELLA THERAPEUTICS, INC. JENKINS GEORGE M Director BUY $125.00 4,000 $500,000 187,171
2026-02-28 00:11 2026-02-26 BBIO BridgeBio Pharma, Inc. Apuli Maricel Officer SELL $66.00 2,000 $132,000 121,945
2026-02-28 00:20 2026-02-26 ABCL AbCellera Biologics Inc. Thermopylae Holdings Ltd. 10% owner BUY $3.27 177,457 $580,284 56,096,097
2026-02-28 00:42 2026-02-25 QURE uniQure N.V. KLEMT CHRISTIAN Officer SELL $23.86 6,217 $148,338 211,513
2026-02-28 01:00 2026-02-25 ABBV AbbVie Inc. Siatis Perry C Officer OPT+S $230.00 22,381 $5,147,630 38,137
2026-02-28 00:44 2026-02-05 MANE Veradermics, Inc CHILDS JOHN W Director BUY $17.00 294,117 $4,999,989 294,117
2026-02-28 05:00 2026-02-26 WVE Wave Life Sciences Ltd. Francis Chris Officer OPT+S $15.05 33,194 $499,593 61,867
2026-02-28 02:54 2026-02-25 TNGX Tango Therapeutics, Inc. Crystal Adam Officer SELL $12.77 54,345 $694,208 132,873
2026-02-28 03:00 2026-02-25 QTTB Q32 Bio Inc. Violette Shelia M. Officer SELL $4.51 2,815 $12,708 55,569
2026-02-28 03:00 2026-02-25 QTTB Q32 Bio Inc. Morrison Jodie Pope Director, Officer SELL $4.51 9,896 $44,675 89,104
2026-02-28 03:00 2026-02-26 AXSM Axsome Therapeutics, Inc. Jacobson Mark L. Officer OPT+S $161.88 35,378 $5,726,991 0
2026-02-28 03:00 2026-02-26 AXSM Axsome Therapeutics, Inc. Coleman Mark Director SELL $161.11 25,000 $4,027,750 47,140
2026-02-28 03:00 2026-02-25 QTTB Q32 Bio Inc. Kalowski Lee Officer SELL $4.51 3,995 $18,035 35,943
2026-02-28 01:19 2026-02-27 BHC Bausch Health Companies Inc. Carson Seana Officer SELL $5.95 8,388 $49,909 809,258
2026-02-28 00:49 2026-02-25 IRON Disc Medicine, Inc. Franchi Jean M. Officer SELL $69.06 353 $24,377 70,990
2026-02-28 00:49 2026-02-25 QURE uniQure N.V. Kapusta Matthew C Director, Officer SELL $23.86 12,378 $295,339 639,076
2026-02-28 00:13 2026-02-25 BCAX Bicara Therapeutics Inc. Cohlhepp Ryan Director, Officer OPT+S $18.04 3,631 $65,501 209,641
2026-02-28 00:05 2026-02-25 CLYM Climb Bio, Inc. Thomas Stephen Basil Director SELL $7.01 50,000 $350,255 154,657
2026-02-27 22:48 2026-02-27 ABCL AbCellera Biologics Inc. Booth Andrew Officer BUY $3.42 42,600 $145,692 195,600
2026-02-27 16:33 2026-02-25 LXRX LEXICON PHARMACEUTICALS, INC. DEBBANE RAYMOND Director BUY $1.49 2,000 $2,980 1,906,186
2026-02-27 00:40 2026-02-24 CTNM Contineum Therapeutics, Inc. Stengone Carmine N. Director, Officer OPT+S $16.02 7,100 $113,728 14,954
2026-02-27 00:39 2026-02-24 CTNM Contineum Therapeutics, Inc. Lorrain Daniel S. Officer OPT+S $16.02 8,124 $130,164 156,052
2026-02-27 05:40 2026-02-24 NAMS NewAmsterdam Pharma Co N.V. Davidson Michael H. Director, Officer OPT+S $34.53 306,293 $10,575,103 174,144
2026-02-27 04:39 2026-02-26 BMRN BIOMARIN PHARMACEUTICAL INC Friberg Gregory R Officer SELL $60.38 6,326 $381,937 37,578
2026-02-27 04:31 2026-02-26 BMRN BIOMARIN PHARMACEUTICAL INC Davis George Eric Officer SELL $61.36 26,061 $1,599,103 72,453
2026-02-27 03:09 2026-02-24 PAHC PHIBRO ANIMAL HEALTH CORP BENDHEIM JACK Director, Officer, 10% owner SELL $52.27 21,120 $1,103,938 1,480
2026-02-27 02:55 2026-02-25 VRTX VERTEX PHARMACEUTICALS INC / MA Tatsis Ourania Officer SELL $486.35 260 $126,451 46,763
2026-02-27 02:48 2026-02-25 VRTX VERTEX PHARMACEUTICALS INC / MA McKechnie Duncan Officer SELL $487.65 4,910 $2,394,365 17,559
2026-02-27 02:50 2026-02-25 VRTX VERTEX PHARMACEUTICALS INC / MA Sachdev Amit Officer SELL $486.35 1,846 $897,802 55,570
2026-02-27 01:56 2026-02-25 VRTX VERTEX PHARMACEUTICALS INC / MA Ambrose Kristen Officer SELL $486.35 223 $108,456 6,981
2026-02-27 02:00 2026-02-25 VRTX VERTEX PHARMACEUTICALS INC / MA Atkinson Edward Morrow III Officer SELL $486.35 668 $324,882 18,432
2026-02-27 02:01 2026-02-25 VRTX VERTEX PHARMACEUTICALS INC / MA Biller Jonathan Officer SELL $486.35 945 $459,601 13,659
2026-02-27 02:06 2026-02-25 VRTX VERTEX PHARMACEUTICALS INC / MA Bunnage Mark E. Officer SELL $486.35 620 $301,537 7,284
2026-02-27 00:47 2026-02-24 ORIC Oric Pharmaceuticals, Inc. Piscitelli Dominic Officer OPT+S $13.51 52,000 $702,686 68,148
2026-02-26 00:00 2026-02-23 AMLX Amylyx Pharmaceuticals, Inc. Common Stock Mazzariello Gina Officer SELL $14.14 3,419 $48,352 141,274
2026-02-26 00:05 2026-02-23 IRWD IRONWOOD PHARMACEUTICALS INC Martini Gregory S. Officer SELL $3.73 21,944 $81,888 160,601
2026-02-26 00:05 2026-02-23 IRWD IRONWOOD PHARMACEUTICALS INC John Minardo Officer SELL $3.73 36,492 $136,177 363,886
2026-02-26 00:05 2026-02-23 IRWD IRONWOOD PHARMACEUTICALS INC Shetzline Michael Officer SELL $3.73 32,582 $121,586 521,425
2026-02-26 00:05 2026-02-23 IRWD IRONWOOD PHARMACEUTICALS INC Gaskins Tammi L Officer SELL $3.73 21,526 $80,329 213,738
2026-02-26 00:05 2026-02-23 IRWD IRONWOOD PHARMACEUTICALS INC MCCOURT Thomas A Director, Officer SELL $3.73 198,283 $739,933 1,489,002
2026-02-26 00:05 2026-02-23 IRWD IRONWOOD PHARMACEUTICALS INC Silver Ronald Officer SELL $3.73 24,173 $90,206 252,636
SHOW ENTRIES

Sector-Wide Insider Alpha

Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.

SEC Filings in Pharmaceutical Preparations

Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.